New ‘first-in-man’ data to be presented at ESMO

This year’s ESMO Congress will provide us with a first glimpse at some new drugs that may eventually become cancer treatments in the future.

Among these, data for several drugs with novel mechanisms to target anaplastic lymphoma kinase (ALK) activity will be presented during tomorrow’s Developmental Therapeutics session. Translocations of the ALK gene occur in a small subset of patients with non-small-cell lung cancer (NSCLC) that result in constitutive ALK activation and promotion of carcinogenesis. New drugs targeting ALK activity being reported tomorrow include AUY922, a non-geldanamycin HSP90 inhibitor; AP26113, an orally-active tyrosine kinase inhibitor (TKI) of the L1196M mutant form of ALK; LDK378, an adenosine  triphosphate (ATP) competitive inhibitor of ALK; and CH5424802, a selective ALK inhibitor capable of blocking both native ALK and the L1196M variant. Another ‘first-in-man’ study will also be reported as a late-breaking abstract in Sunday’s prostate cancer poster discussion session. This presentation´will include data from a Phase 1/2 dose escalation study of ODM-201, a novel, next generation androgen receptor (AR) antagonist, in men with progressive, metastatic castration-resistant prostate cancer (mCRPC). ODM-201 is thought to inhibit AR activity by blocking nuclear translocation, and may build on the established efficacy of earlier AR antagonists since it lacks partial agonist activity.
Don’t miss these important sessions to find out more regarding the safety and early efficacy of these new agents.
Session Info: Developmental therapeutics
Day/Date: Saturday, September 29, 2012
Session Time: 11:00 – 12:45
Room: Hall E

Abstract: 438O Phase II activity of the HSP90 inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell
lung cancer (NSCLC) Presenter: Professor Enrique Philippe, Vall d’Hebron University Hospital, Barcelona, Spain Abstract: 439O A first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies Presenter: Dr Scott Gettinger, Yale University School of Medicine, New Haven, USA Abstract: 440O Results of a first-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumours
Presenter: Dr Alice Shaw, Harvard Medical School, Boston, USA

Abstract: 441O Phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC; safety and efficacy interim results of the phase II portion
Presenter: Dr Makoto Nishio, Thoracic Oncology Centre, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
Session Info: Poster Discussion, genitourinary tumours, prostate
Day/Date: Sunday, September 30, 2012
Session Time: 13:00 – 14:00
Room: Hall C
Abstract: LBA25_PR ARADES trial: A first-in-man, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ODM-201 in patients (pts) with progressive metastatic castrationresistant prostate cancer (mCRPC)
Presenter: Dr Christophe Massard, Institut de Cancérologie Gustave Roussy, Villejuif, France